ESR1 mutations account for a common factor affecting ESR1 transcription in breast cancer [177], which predominantly occur in patients with HR+ breast cancer who have undergone a period of aromatase inhibitor (AI) treatment. Here, CYP19A1 is linked to breast cancer.